Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Musculoskeletal and connective tissue disorders – page 18

  • 865 clinical trials
  • 357 recruiting
  • 328 conditions
  • 28 countries

Conditions in this area

328 conditions with trials, the busiest first

Rheumatoid arthritis75Osteoarthritis62Systemic lupus erythematosus61Psoriatic arthropathy46Myasthenia gravis43Systemic scleroderma39Sjogren's syndrome29Duchenne muscular dystrophy28Soft tissue sarcoma28Axial spondyloarthritis21Juvenile idiopathic arthritis21Back pain19Ewing's sarcoma19Lupus nephritis18Spinal muscular atrophy17Dermatomyositis15Cutaneous lupus erythematosus14Glycogen storage disease type II14Myotonic dystrophy12Osteochondrodysplasia12Osteosarcoma12Rhabdomyosarcoma11Sarcoma11Osteoporosis10+304

Clinical trials in Musculoskeletal and connective tissue disorders

865 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

865 clinical trials

Osteoarthritis

Recruiting

Study on the Tolerance of Intra-Articular Injection of Autologous Stromal Vascular Fraction for Adults with Thumb Arthritis (Rhizarthrosis)

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Autologous Adipose Tissue-Derived Stromal Vascular Fraction
  • Sponsor:Centre Hospitalier Universitaire Rouen

Fibrodysplasia ossificans progressiva

Recruiting

Study on the Effectiveness of INCB000928 for Patients with Fibrodysplasia Ossificans Progressiva

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Incb000928
  • Sponsor:Incyte Corp.

Psoriatic arthropathy+1

Recruiting

Study on the Safety and Immune Response of Shingrix Vaccine in Patients with Psoriasis or Psoriatic Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E
  • Sponsor:Justus-Liebig-Universitaet Giessen

Osteoarthritis

Recruiting

Study on Treating Knee Osteoarthritis with N-TEC Implant for Patients with Patellofemoral Osteoarthritis

InvestigationalNo placebo
Countries:CroatiaCroatia
  • Participants:18–64 years
  • Substances:N-Tec
  • Sponsor:Universitaetsspital Basel

Rheumatoid arthritis+1

Recruiting

Study on Morning vs. Evening Dosing of Tofacitinib for Patients with Rheumatoid or Psoriatic Arthritis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Tofacitinib
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Systemic sclerosis pulmonary

Recruiting

Study of rituximab and mycophenolate mofetil combination therapy compared to placebo for patients with interstitial lung disease related to systemic sclerosis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Muscle spasticity

Recruiting

Study of individualized doses of botulinum toxin type A (incobotulinumtoxin) in adults with severe spasticity caused by brain damage

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Botulinum Toxin Type A
  • Sponsor:Dra. Nuria Gutierrez Dubón

Duchenne muscular dystrophy

Recruiting

Study on the Safety and Effects of Givinostat in Young Children with Duchenne Muscular Dystrophy (Ages 2 to Less Than 6 Years)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Inclusion body myositis

Recruiting

Study on Ruxolitinib for Treating Inclusion Body Myositis in Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Assistance Publique Hopitaux De Paris

Myotonic dystrophy

Recruiting

Long-Term Safety and Efficacy Study of Mexiletine Hydrochloride for Patients with Myotonic Dystrophy Type 1 and Type 2

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mexiletine Hydrochloride
  • Sponsor:Lupin Atlantis Holdings SA

Dermatomyositis+4

Recruiting

Study on Upadacitinib for Patients with Idiopathic Inflammatory Myopathies After Stopping IVIG

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:Medical University Of Vienna

Anaplastic large cell lymphoma T- and null-cell types+1

Recruiting

Study of Brigatinib for Children and Young Adults with ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors, or Other Solid Tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Brigatinib
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Substances studied in this area

The therapies tested most often in Musculoskeletal and connective tissue disorders trials.

Sodium Chloride47 clinical trialsParacetamol32 clinical trialsTocilizumab29 clinical trialsMethotrexate25 clinical trialsAdalimumab24 clinical trialsRituximab23 clinical trialsCyclophosphamide20 clinical trialsEtanercept20 clinical trialsBaricitinib17 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.